Lv4
410 积分 2023-10-07 加入
Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974
24天前
已完结
Glypican-3-targeted therapy in hepatocellular carcinoma: biological insights and therapeutic strategies
24天前
已完结
T cell engagers in autoimmune diseases
24天前
已完结
Cancer burden and control in China: landscape, trends and challenges
24天前
已完结
Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies
1个月前
已完结
Unlocking the potential of T cell engagers in solid tumors
1个月前
已完结
IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
1个月前
已完结
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
1个月前
已完结
Multispecific T-cell engagers attract cancer drug developers
1个月前
已完结
Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co-Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study
4个月前
已完结
皖公网安备34019202002308
